Browse

First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer

Cited 25 time in Web of Science Cited 31 time in Scopus
Authors
Park, Se Hoon; Bang, Soo-Mee; Cho, Eun Kyung; Baek, Jeong Heum; Oh, Jae Hwan; Im, Seock Ah; Park, Young Suk; Shin, Dong Bok; Lee, Jae Hoon
Issue Date
2004-08-28
Publisher
Karger
Citation
Oncology. 2004;66(5):353-7.
Keywords
Adenocarcinoma/*drug therapyAdultAgedAntineoplastic Combined Chemotherapy Protocols/*therapeutic useCamptothecin/*administration & dosage/adverse effects/*analogs &derivativesColorectal Neoplasms/*drug therapyDeoxycytidine/*administration & dosage/adverse effects/*analogs &derivativesFemaleFluorouracil/analogs & derivativesHumansLeukopenia/chemically inducedMaleMiddle AgedSurvival Rate
Abstract
OBJECTIVE: The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma. METHODS: Patients with histologically proven advanced colorectal adenocarcinoma received a first-line chemotherapy with irinotecan 240 mg/m2 on day 1 and capecitabine 2,000 mg/m2/day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest. Treatment was repeated every 3 weeks. RESULTS: Thirty-nine patients were registered, and 36 were assessable for responses. Sixteen objective responses (44%) were observed with a median response duration of 6.9 months. Stable disease was documented in 14 cases (39%). The median time to progression was 6.7 months. The median overall survival was not reached at the time of analysis, and the 1-year survival rate was 67%. Two patients died: 1 due to sepsis not complicating myelosuppression, and 1 patient, known as a hepatitis B virus carrier prior to chemotherapy, died of hepatic failure, the cause of which was not clinically verified. Frequently encountered therapy-related events were leukopenia and gastrointestinal side effects including diarrhea. Severe hand-and-foot syndrome was observed in only 1 patient. CONCLUSIONS: The combination chemotherapy of irinotecan and capecitabine is an active and tolerable regimen for advanced colorectal adenocarcinoma, but the observed deaths suggest a future randomized trial that requires a cautious patient selection.
ISSN
0030-2414 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15331921

http://hdl.handle.net/10371/29353
DOI
https://doi.org/10.1159/000079482
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse